Jafron e-Seminar
Walk with the Luminaries

Question Form
First name
Last name
E-mail address
Phone number
Please call me back
Your question

By ticking the hook, I agree that the data collected from me for the processing of my request are collected and stored electronically. This consent can be revoked at any time with a message to us. Further information can be found in the privacy policy.

Monthly FAQ Summary
Q: What are the indications for HA cartridges?
A: According to clinical practices and studies, a disposable hemoperfusion cartridge is indicated to remove the following substances: • Inflammatory mediators and cytokines such as IL-1, IL-6, IL-8, IL-10, TNF-a. • Overdosed with drugs and poisons such as organophosphorus, paraquat, and carbamazepine. • Accumulated B2-MG, PH, leptin, and protein-bound toxins in end-stage renal disease hemodialysis-related complication. • Excessive triglyceride and cholesterol in hyperlipidemia severe acute pancreatitis. • Other substances: bilirubin, myoglobin.
Q: Could you illustrate the safety and biocompatibility of Jafron cartridges?
A: The biocompatibility of the cartridges has been evaluated both in vitro and in vivo. In vitro, CT imaging showed an excellent distribution of the flow inside the HA cartridges without channeling phenomena. The cytotoxicity test demonstrated that HA cartridges carried out an optimal level of biocompatibility, and their use was not associated with adverse reactions. Clinically, the publications did not show significant adverse reactions related to Jafron hemoperfusion.
Q: What are the adsorption principles and the clinical applications of the HA230 hemoadsorption cartridge?
A: lt mainly removes poisons and overdose drugs with a molecular weight of 500Da~10KDa orhydrophobic or high protein-binding properties. The clinical applications could be divided into poisons and drug overdose as listed below: a) Parquat poisoning, Acute severe organophosphate poisoning (ASOP), 2,4-Dinitrophenol.Snake venom, Mushroom poisoning, Abrin, Paroxetine, Thallium, Aconitine, etc. b) Methotrexate (MTX), Ticagrelor, Carbamazepine. Paroxetine, Amitriptyline, Digoxin.Acetaminophen, lmipramine, Amlodipine (CCBs), etc.
Q: What is the recommended treatment scheme for HA230?
A: a) The treatment should be initiated as early as possible (4-6 h from exposure to poison or drug, the therapy after 12 hours of the exposure is less effective). b) The recommended scheme is 3-5 cartridges for each patient, with a suggested duration of 3-4 hours for each cartridge and no more than 12 hours. c) Hemoadsorption should be carried out more frequently at the beginning (1-3 cartridges/day). d) The treatment frequency and duration could be adjusted according to the type of poison/drug and the patient' s condition.
Q: What are the expected benefits of using HA230 hemoadsorption?
A: According to the previous publications, hemoadsorption HA230 therapy could benefit on: a) Accelerate the elimination of poison and overdose drugs. b) Stabilize the hemodynamic status.